Avadel Pharmaceuticals (STU:AWK) Additional Paid-In Capital : €804.10 Mil(As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Additional Paid-In Capital?

Avadel Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€798.20 Mil) to Dec. 2023 (€784.45 Mil) but then increased from Dec. 2023 (€784.45 Mil) to Mar. 2024 (€804.10 Mil).

Avadel Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€486.17 Mil) to Dec. 2022 (€556.76 Mil) and increased from Dec. 2022 (€556.76 Mil) to Dec. 2023 (€784.45 Mil).

Avadel Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Avadel Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Additional Paid-In Capital Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

390.95

466.01

486.17

556.76

784.45

Avadel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															563.40	783.28	798.20	784.45	804.10

Avadel Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Avadel Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (STU:AWK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.